One of longevity’s favorite drugs just took a hit.
A new human dataset is circulating in longevity circles, and it is awkward for rapamycin fans.
Over roughly a decade, survival looked nearly identical between kidney transplant patients taking the drug and those who weren’t.
Does that mean the biohacking world’s darling is a bust?
The answer is more complicated, and one detail about the patients changes everything.
Jump to:
The Numbers Behind the Headline
The retrospective analysis compared 4,885 transplant patients on rapamycin with 6,589 who were not. Follow-up reached a median of 11 years, with adjustments for 18 confounding factors.
Median survival landed at 64.6 years versus 64.3 years. Statistically, that is a tie.
One caution: these figures have circulated mainly through online discussion, and the underlying paper could not be independently pinned down. Treat the exact statistics as provisional until the full publication is in hand.
Why Mice Lit the Fuse
Rapamycin’s celebrity status traces back to a landmark 2009 paper in Nature by Harrison and colleagues. Mice started on the drug at 600 days old, roughly late middle age for a human, lived 9% longer (males) and 14% longer (females).
Even late-life treatment worked, which made rapamycin the first drug to robustly extend mammalian lifespan. Researchers pointed to the mTOR pathway, a master regulator of cell growth. Dialing down mTORC1 is thought to nudge cells toward autophagy, the cleanup and repair mode linked with longevity.
Mice, however, are not people. A PubMed Central review of rapamycin for longevity notes that the main early human signal was a stronger immune response to influenza vaccines, not longer life or better healthspan.
The Catch: Transplant Patients Are Not Biohackers
Here is where the story gets nuanced. Transplant recipients take daily immunosuppressive doses, while longevity enthusiasts typically take around 5 to 6 mg once weekly.
Different dose, different rhythm, different biology. Add pre-existing organ failure, compromised immunity, and a pile of other medications, and the comparison group is deeply tangled.
So what can the study actually say?
- What it does show: daily rapamycin in a very sick population did not visibly extend survival.
- What it can’t show: whether low, intermittent doses help healthy 45-year-olds.
- Why it still matters: it is among the longest human follow-ups available, and it failed to deliver a longevity signal.
When the Poster Children Step Back
Tech entrepreneur Bryan Johnson once described his regimen as the most intense in the field, stacked with metformin and more than 100 daily supplements in a protocol reportedly costing $2 million a year.
The most aggressive rapamycin protocol of anyone in the industry.
In 2024, Johnson quit. He cited chronic infections, metabolic disturbances, and an inability to detect any meaningful benefit despite exhaustive biomarker tracking.
Online chatter goes further. Reddit communities devoted to Dr. Peter Attia reported in late 2025 that he stopped taking the drug after mouth sores, a known side effect. That claim is anecdotal and unconfirmed. Andrew Huberman, meanwhile, was reported to have said he is:
Not a fan.
Not Everyone Has Bailed
Matt Kaeberlein, PhD, a University of Washington gerontologist, remains a prominent advocate and has taken the drug in cycles himself. His Dog Aging Project reported improved cardiac function in middle-aged dogs, a promising bridge between mouse and human data.
Promising, though, is not proven. Dogs share homes with people, not biology.
Side Effects Worth Knowing
Clinical literature documents a consistent list of downsides. Self-experimenters have echoed several.
- Mouth sores (oral ulcers)
- Impaired wound healing
- Elevated lipids
- Higher infection risk
- Metabolic disturbances
A Conflict-of-Interest Red Flag
Healthy-adult data is thin. One year-long trial reportedly missed its primary endpoint, and every author was said to work for the drug’s manufacturer.
Another preprint, posted to bioRxiv in October 2024, leaned on epigenetic clocks, a shaky endpoint paired with uncertain dosing. Nobody considers it definitive.
Telehealth Makes It Easy
Meanwhile, online clinics have been prescribing rapamycin after minimal questionnaires, a trend peer-reviewed literature flags as a regulatory and safety concern. Rapamycin is FDA-approved for transplant immunosuppression only. Longevity use is entirely off-label.
Experts in regulation and bioethics would call for genuine placebo-controlled trials in healthy populations before wider adoption.
What to Do With All This
Rapamycin is not debunked. It is unproven in healthy humans, and that gap is the real story.
- Talk to a physician before considering any off-label mTOR inhibitor, especially one obtained through a quick online form.
- Skip extrapolation: mouse lifespan charts and transplant survival curves each answer different questions.
- Lean on proven habits. Exercise, sleep, diet quality, and social connection carry long-term human data tied to lower mortality.
- Watch for real trials in healthy adults. Those results, not influencer anecdotes, will settle this.
Longevity medicine rewards patience. Boring fundamentals still beat the shiny pill, at least until better evidence arrives.
Sources
- PubMed Central review on rapamycin for longevity: https://pmc.ncbi.nlm.nih.gov/articles/PMC12226543/
